Vertex Pharmaceuticals

Yahoo Finance • 13 hours ago

Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations

Zealand Pharma Eric RojasVP, Head of Investor Relations·GlobeNewswire Inc. Press release – No. 7 / 2026 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations Bringing significant experience from Vertex Pha... Full story

Yahoo Finance • 4 days ago

Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $612 from $596 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter... Full story

Yahoo Finance • 6 days ago

Nasdaq, S&P 500, Dow futures slip as hopes of U.S.-Iran resolution fade

[Lower Manhattan skyscrapers, New York City] Stock index futures were lower before the opening bell as hopes of a resolution to the U.S.-Iran conflict waned following warnings from President Donald Trump of a major escalation. Nasdaq 100... Full story

Yahoo Finance • 8 days ago

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

SAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and licen... Full story

Yahoo Finance • 8 days ago

Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position?

Investors looking for stocks that can turn a modest portfolio into a multimillion-dollar nest egg often find what they're looking for in the biotech industry. For several years, CRISPR Therapeutics(NASDAQ: CRSP) has been attracting investm... Full story

Yahoo Finance • 12 days ago

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have outperformed the market lately as the 1.1% drawdown for healthcare stocks over the p... Full story

Yahoo Finance • 18 days ago

Prediction: The Trump Bull Market Is About to End -- but These Stocks Will Rise Anyway

Key Points Multiple headwinds could bring the bull market to a halt. Stocks positioned to rise even during a market downturn include Berkshire Hathaway, Enbridge, and Vertex Pharmaceuticals.10 stocks we like better than Vertex Pharmaceuti... Full story

Yahoo Finance • 18 days ago

Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026.Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550 On March 19, 2026, Vertex Pharmaceuticals Incorporated (NA... Full story

Yahoo Finance • 18 days ago

Jim Cramer on Corteva, Inc.: “I Would Continue to Own the Stock”

Jim Cramer reviewed Corteva, Inc. (NYSE:CTVA) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. Toward the end of the lightning round, a caller asked for Cramer’s thoughts on the stock, and he... Full story

Yahoo Finance • 19 days ago

2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players. This dynamic c... Full story

Yahoo Finance • 22 days ago

Truist Raises Vertex (VRTX) Price Target Following Phase 3 Trial Results

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high profit margin stocks to buy. On March 10, Truist Securities boosted its price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $525 from $490, while... Full story

Yahoo Finance • 22 days ago

CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?

Key Points CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an approved therapy in Casgevy, but its business remains deeply unprofitable. CRISPR's financial positio... Full story

Yahoo Finance • 23 days ago

How The Vertex Pharmaceuticals (VRTX) Story Is Shifting Toward Nephrology And Beyond Cystic Fibrosis

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Vertex Pharmaceuticals now carries a fair value estimate of US$547.72, compared with the prior US$504.04, as analysts refresh thei... Full story

Yahoo Finance • 24 days ago

New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST

Featured Companies Include FreeCast (NASDAQ:CAST), KLED.ai, Lantern Pharma (NASDAQ:LTRN), and BlackBarn Restaurant NEW YORK CITY, NY / ACCESS Newswire / March 21, 2026 / New to The Street, one of the longest-running U.S. and international... Full story

Yahoo Finance • 25 days ago

7 Companies That Look Primed to Beat on Earnings

We looked for promising names in materials and healthcare, and found some investments that should thrive in today’s economy. Continue Reading... Full story

Yahoo Finance • 28 days ago

Block upgraded, Starbucks downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Truist upgraded Block (XYZ) to Buy fro... Full story

Yahoo Finance • 29 days ago

Worried About a Market Crash? 3 ETFs to Buy to Sleep Well At Night

Quick Read SPDR Gold Trust (GLD) has surged 67% over the past year and is up 16% year-to-date by serving as a store of value when geopolitical stress rises, while iShares 20+ Year Treasury Bond ETF (TLT) yields 4.6% but has fallen 2.5% re... Full story

Yahoo Finance • 29 days ago

Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now?

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months. Cathie Wood’s ARK increased its stake in... Full story

Yahoo Finance • 30 days ago

1 Momentum Stock to Research Further and 2 We Ignore

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance. But not every company with... Full story

Yahoo Finance • last month

Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and CVS Health in focus

Wall Street’s major indexes ended lower on Friday as investors digested a fresh batch of economic data, highlighted by the latest PCE inflation and GDP reports. The benchmark S&P 500 ended -0.6%, the blue-chip Dow closed -0.2%, and the te... Full story